STOCK TITAN
  1. Home
  2. Sec-filings
  3. STE
  4. [Form 4] STERIS plc Insider Trading Activity

STERIS STE executive trades: options exercised, 10,710 shares held

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

STERIS plc (STE) reported insider transactions by its Sr. VP and GM, Life Sciences, on November 21, 2025. The officer exercised employee stock options to buy 2,872 ordinary shares at $114.22 and 2,136 ordinary shares at $147.05, then sold the same numbers of shares in two sales at $262 per share. Following these transactions, the officer beneficially owned 10,710 ordinary shares.

As of November 21, 2025, 4,003 of these 10,710 ordinary shares are restricted, with restrictions scheduled to lapse in several tranches between June 1, 2026 and June 5, 2028. The reported stock options are described as fully vested and now show 0 derivative securities remaining after the exercises.

Positive

  • None.

Negative

  • None.
Insider Madsen Julia
Role Sr. VP and GM, Life Sciences
Sold 5,008 shs ($1.31M)
Type Security Shares Price Value
Exercise Employee Stock Option (right to buy) 2,872 $0.00 --
Exercise Employee Stock Option (right to buy) 2,136 $0.00 --
Exercise Ordinary Shares 2,872 $114.22 $328K
Sale Ordinary Shares 2,872 $262.00 $752K
Exercise Ordinary Shares 2,136 $147.05 $314K
Sale Ordinary Shares 2,136 $262.00 $560K
Holdings After Transaction: Employee Stock Option (right to buy) — 0 shares (Direct); Ordinary Shares — 13,582 shares (Direct)
Footnotes (1)
  1. As of November 21, 2025, 4,003 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 578 on June 1, 2026, 352 on June 2, 2026; 666 on June 3, 2026; 542 on June 4, 2026; 666 on June 3, 2027; 542 on June 4, 2027 and 666 on June 5, 2028. This option is fully vested.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Madsen Julia
(Last) (First) (Middle)
70 SIR JOHN ROGERSON'S QUAY
(Street)
DUBLIN 2 L2 D02 R296
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
STERIS plc [ STE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Sr. VP and GM, Life Sciences
3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 11/21/2025 M 2,872 A $114.22 13,582(1) D
Ordinary Shares 11/21/2025 S 2,872 D $262 10,710(1) D
Ordinary Shares 11/21/2025 M 2,136 A $147.05 12,846(1) D
Ordinary Shares 11/21/2025 S 2,136 D $262 10,710(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $114.22 11/21/2025 M 2,872 (2) 05/31/2028 Ordinary Shares 2,872 $0 0 D
Employee Stock Option (right to buy) $147.05 11/21/2025 M 2,136 (2) 05/31/2029 Ordinary Shares 2,136 $0 0 D
Explanation of Responses:
1. As of November 21, 2025, 4,003 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 578 on June 1, 2026, 352 on June 2, 2026; 666 on June 3, 2026; 542 on June 4, 2026; 666 on June 3, 2027; 542 on June 4, 2027 and 666 on June 5, 2028.
2. This option is fully vested.
Remarks:
/s/ John P. Ubbing, Authorized Representative under Power of Attorney 11/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did STERIS (STE) report in this Form 4?

The filing reports that the Sr. VP and GM, Life Sciences of STERIS plc (STE) exercised fully vested employee stock options and then sold the resulting ordinary shares in open-market transactions on November 21, 2025.

How many STERIS (STE) shares did the officer exercise and sell?

The officer exercised options for 2,872 ordinary shares at $114.22 and 2,136 ordinary shares at $147.05, and then sold 2,872 and 2,136 ordinary shares, respectively, at a sale price of $262 per share.

How many STERIS (STE) shares does the reporting person own after the transactions?

After the reported transactions, the officer beneficially owned 10,710 ordinary shares of STERIS plc.

What portion of the officer’s STERIS (STE) shares are restricted and when do they vest?

As of November 21, 2025, 4,003 of the 10,710 ordinary shares are restricted. The restrictions lapse in tranches of 578, 352, 666, 542, 666, 542, and 666 shares on dates between June 1, 2026 and June 5, 2028.

What happens to the STERIS (STE) employee stock options after these transactions?

The filing shows two employee stock options (rights to buy) with exercise prices of $114.22 and $147.05. Both options are described as fully vested, and after the exercises, the number of derivative securities beneficially owned is reported as 0 for each option.

What is the reporting person’s role at STERIS (STE)?

The reporting person is an officer of STERIS plc, serving as Sr. VP and GM, Life Sciences.